



Menopause

The Journal of The North American Menopause Society

VOLUME 27, ISSUE 10 2020

SDC

Supplemental Digital Content is available.

OPEN

Open Access article.

CONTENTS

Editorials

1099

Age at first childbirth as a predictor of health outcomes later in life among women

Aladdin H. Shadyab, PhD

1101

Bone health and beyond in women with primary ovarian insufficiency: time to narrow the knowledge-action gap in care

Xuezhi (Daniel) Jiang, MD, PhD, FACOG, NCMP

Original Studies

1104

Age at first childbirth in relation to oral health later in life

Seonah Lee, BS, and Sangshin Park, PhD

This study showed that age at first childbirth was associated with increased odds of chewing inconvenience and dental caries. Body mass index mediated the relationships of age at first childbirth and periodontitis and dental caries.

SDC

1110

Bone mass in women with premature ovarian insufficiency: a comparative study between hormone therapy and combined oral contraceptives

Lívia B. Carvalho Gazarra, pharmacist, Camila L. Bonacordi, MD, Daniela A. Yela, MD, PhD, and Cristina Laguna Benetti-Pinto, MD, PhD

Continuous use of a combined oral contraceptive can be considered as an option for hormone therapy in women with premature ovarian insufficiency, according to the preliminary results of this study.

(continued)

Menopause: The Journal of The North American Menopause Society (ISSN 1072-3714) is published monthly for The North American Menopause Society by Wolters Kluwer Health, Inc. Business and production offices are located at Two Commerce Square, 2001 Market St., Philadelphia, PA 19103. All rights reserved. Copyright © 2020 by The North American Menopause Society.

POSTMASTER: Send address changes to *Menopause: The Journal of The North American Menopause Society*, P.O. Box 1610, Hagerstown, MD 21740.

SDC

1117

The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative

Fatima Cody Stanford, MD, MPH, MPA, Hellas Cena, MD, Ginevra Biino, PhD, Olivia Umoren, BS, Monik Jimenez, ScD, Marlene P. Freeman, MD, Aladdin H. Shadyab, PhD, Robert A. Wild, MD, MPH, PhD, Catherine R. Womack, MD, Hailey R. Banack, PhD, and JoAnn E. Manson, MD, DrPH

This study sought to quantify the magnitude of association between putative weight-promoting medications and 3-year weight change in a diverse cohort of postmenopausal women in the Women's Health Initiative. This study demonstrates that several classes of medication are associated with weight gain in postmenopausal women.

1126

Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials

Susan J. Diem, MD, MPH, Andrea Z. LaCroix, PhD, Susan D. Reed, MD, MPH, Joseph C. Larson, MS, Katherine M. Newton, PhD, Kristine E. Ensrud, MD, MPH, Nancy F. Woods, PhD, and Katherine A. Guthrie, PhD

Results from this pooled analysis demonstrate that a variety of treatment approaches provide improvement in health-related quality of life among menopausal women with vasomotor symptoms. Using this information women can select an approach based on most bothersome symptoms and individual preferences.

OPEN

SDC

1137

Abaloparatide followed by alendronate in women ≥ 80 years with osteoporosis: post hoc analysis of ACTIVEExtend

Susan L. Greenspan, MD, Lorraine A. Fitzpatrick, MD, Bruce Mitlak, MD, Yamei Wang, PhD, Nicholas C. Harvey, MD, Chad Deal, MD, Felicia Cosman, MD, and Michael McClung, MD
Sequential treatment with abaloparatide followed by alendronate in this small subgroup of ACTIVEExtend participants suggests abaloparatide is well-tolerated and effective in women aged ≥ 80 years.

1143

Sexual function after tension-free vaginal tape procedure in stress urinary incontinence patients

Ye Zhang, PhD, Xiaochen Song, MD, Jia Kang, PhD, Yidi Ma, PhD, Congcong Ma, PhD, and Lan Zhu, MD

Most women experienced an improvement in sexual function after the tension-free vaginal tape operation, due to less coital incontinence, less fear of incontinence, and fewer negative emotional reactions.

1148

Vaginal pessary continuation in symptomatic pelvic organ prolapse patients with prior hysterectomy

Congcong Ma, PhD, Jia Kang, PhD, Tao Xu, PhD, Ye Zhang, PhD, Yidi Ma, PhD, Shuo Liang, MD, Yujie Hui, MM, Yuhong Wang, MM, and Lan Zhu, MD

A history of pelvic organ prolapse reconstructive surgery and a short total vaginal length were potential risk factors for unsuccessful pessary fitting, whereas age and prolapse score improvement at 3-month were potential predictors for continuation.

1155

A proprotein convertase subtilisin/kexin type 9 inhibitor provides comparable efficacy with lower detriment than statins on mitochondria of oxidative muscle of obese estrogen-deprived rats

Chanisa Thonusin, MD, PhD, Patcharapong Pantiya, BSc, Thidarat Jaiwongkam, BSc, Sasiwan Kerdphoo, MSc, Busarin Arunsak, BSc, Patchareeya Amput, MSc, Siripong Palee, PhD, Wasana Pratchayasakul, PhD, Nipon Chattipakorn, MD, PhD, and Siriporn C. Chattipakorn, DDS, PhD

This study demonstrates that 17 β -estradiol exhibits the greatest level of efficacy on the attenuation of obesity with the least harmful effect on skeletal muscle in a model of menopause with obesity, however its effect on the treatment of hyperlipidemia is inferior to those of standard lipid-lowering agents.

Brief Report

1167

Peripheral vasodilation is reduced during exercise in perimenopausal women with elevated cardiovascular risk

Joaquin U. Gonzales, PhD, David J. Moore, PhD, Steriani Elavsky, PhD, and David N. Proctor, PhD

These preliminary results support the notion that an elevated cardiovascular disease risk may have an additional negative impact on vascular function beyond that reported to occur in healthy women transitioning through menopause.

Clinical Corner

Invited Review

1171

Selective estrogen receptor modulators (SERMs): keys to understanding their function

James H. Liu, MD

This review provides a basic understanding of the current knowledge of selective estrogen receptor modulators (SERMs) pharmacodynamics and will highlight the clinical applications of FDA-approved SERMs.

Review Articles

SDC

1177

Vaginal laser treatment of genitourinary syndrome of menopause: does the evidence support the FDA safety communication?

Julia Z. Guo, BS, Colby Souders, MD, Lynn McClelland, BS, MPH, JD, Jennifer T. Anger, MD, MPH, Victoria C.S. Scott, MD, Karyn S. Eilber, MD, and A. Lenore Ackerman, MD, PhD

Evidence to justify the FDA warning cautioning against the use of vaginal laser devices for genitourinary syndrome of menopause (GSM) was not found either in the medical literature or by searching relevant databases for adverse events. The FDA warning requires revision, clarifying the risks of vaginal laser therapy specifically for GSM and allowing women to participate in decision making about treatment modalities.

SDC

1185

Menopause and frailty: a scoping review

Haihui Ruan, BSN, Junping Hu, BSN, Jinzhu Zhao, BSN, Hongxia Tao, BSN, Junting Chi, BSN, Xiaodan Niu, BSN, Jing Zhang, BSN, and Yanhong Wang, PhD

This study found that early menopause, hysterectomy, low free testosterone levels, and high C-reactive protein levels may increase the likelihood of frailty among postmenopausal women and the relationship between estrogen and frailty are conflicting.

Letters to the Editor

SDC

1196

Wolters Kluwer Health, Inc., and The North American Menopause Society cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. All advertising material published in this journal is expected to conform to regulatory and medical standards. The appearance of advertising in this publication does not constitute a guarantee or endorsement by The North American Menopause Society or Wolters Kluwer Health, Inc., of the quality or value of such a product or service or any claims made by its marketer.

Permissions and photocopying: For permission and/or rights to use content for which the copyright holder is Wolters Kluwer or the society we have partnered with the Copyright Clearance Center to provide permissions for our products through their RightsLink service, please go to the journal's website and after clicking on the relevant article, click on the "Get Content & Permissions" link under the "Article Tools" box that appears on the right side of the page. For questions about the Rightslink service, e-mail customer-care@copyright.com or call 877-622-5543 (U.S. Only) or 978-777-9929. Permissions FAQs and information on author's permission requests are available at <https://shop.lww.com/journal-permission>. For additional permission inquiries, please contact Permissions@LWW.com. For translation rights requests, contact TranslationRights@wolterskluwer.com. For license to republish and distribute requests, contact HealthLicensing@wolterskluwer.com. For special projects and reprints (U.S./Canada), contact Alan Moore at Alan.Moore@wolterskluwer.com or reprintsolutions@wolterskluwer.com. For special projects and reprints (non-U.S./Canada), contact Avia Potashnik at Avia.Potashnik@wolterskluwer.com or International-Reprints@wolterskluwer.com.

Menopause: The Journal of The North American Menopause Society is a registered trademark of The North American Menopause Society.

Menopause: The Journal of The North American Menopause Society (ISSN 1072-3714) is published monthly by Wolters Kluwer Health, Inc., at 14700 Citicorp Drive, Bldg 3, Hagerstown, MD 21742. Business offices are located at Two Commerce Square, 2001 Market St., Philadelphia, PA 19103. **Annual subscription rate:** \$610.

Copyright © 2020 by The North American Menopause Society. All rights reserved. Printed in the USA.